TNF: A key neuroinflammatory mediator of neurotoxicity and neurodegeneration in models of parkinson's disease

Advances in Experimental Medicine and Biology

Volumn 691, Issue , 2011, Pages 539-540

  McCoy, Melissa K ^a   Ruhn, Kelly A ^a   Blesch, Armin ^b   Tansey, Malú G ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR; AUTACOID; TUMOR NECROSIS FACTOR ALPHA;

CONFERENCE PAPER; CYTOKINE PRODUCTION; DOPAMINERGIC NERVE CELL; GENETIC ASSOCIATION; HUMAN; INCIDENCE; INFLAMMATION; MICROGLIA; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; ARTICLE; DISEASE MODEL; METABOLISM; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; RAT; TOXICITY AND INTOXICATION;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION MEDIATORS; NERVE DEGENERATION; NEURONS; NEUROTOXICITY SYNDROMES; PARKINSON DISEASE; RATS; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79954435887     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-6612-4_56     Document Type: Conference Paper

References (12)

1. Lee JK, Tran T, Tansey MG (2009) Neuroinflammation in Parkinson's Disease. J Neuroimmune Pharmacol 4:419-429
2. Chen H et al (2005) Nonsteroidal antiinflammatory drug use and the risk of Parkinson's disease. Ann Neurol 59:988-989
3. Chen H (2003) et al Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 60(8):1059-1064
4. Samii A et al (2009) NSAID Use and the risk of Parkinson's disease: Systematic review and meta-analysis of observational studies. Drugs Aging 26(9):769-779
5. Tansey MG, Goldberg MS (2010) Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37:510-518
6. McGuire SO et al (2001) Tumor necrosis factor alpha is toxic to embryonic mesencephalic dopamine neurons. Exp Neurol 169(2):219-230
7. Boka, G et al (1994) Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett 172(1-2):151-154
8. Mogi M et al (1994) Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 165(1-2):208-210
9. NishimuraMet al (2001) Tumor necrosis factor gene polymorphisms in patients with sporadic Parkinson's disease. Neurosci Lett 311(1):1-4
10. Steed PM et al (2003) Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science 301(5641):1895-1898
11. McCoy MK et al (2006) Blocking soluble tumor necrosis factor signaling with dominantnegative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J Neurosci 26(37): 9365-9375
12. McCoy MK et al (2008) Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats. Mol Ther 16(9): 1572-1579